1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Ahn-Gook Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013

Ahn-Gook Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 51 pages

Ahn-Gook Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Ahn-Gook Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013” provides data on the Ahn-Gook Pharmaceutical Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ahn-Gook Pharmaceutical Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Ahn-Gook Pharmaceutical Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Ahn-Gook Pharmaceutical Co., Ltd. - Brief Ahn-Gook Pharmaceutical Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ahn-Gook Pharmaceutical Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ahn-Gook Pharmaceutical Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Ahn-Gook Pharmaceutical Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Ahn-Gook Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Ahn-Gook Pharmaceutical Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Ahn-Gook Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Ahn-Gook Pharmaceutical Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Ahn-Gook Pharmaceutical Co., Ltd. and identify potential opportunities in those areas.

Table Of Contents

Ahn-Gook Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Ahn-Gook Pharmaceutical Co., Ltd. Snapshot 6
Ahn-Gook Pharmaceutical Co., Ltd. Overview 6
Key Information 6
Key Facts 6
Ahn-Gook Pharmaceutical Co., Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline Products Glance 12
Ahn-Gook Pharmaceutical Co., Ltd. - Late Stage Pipeline 12
Phase III Products/Combination Treatment Modalities 12
Ahn-Gook Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Ahn-Gook Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Ahn-Gook Pharmaceutical Co., Ltd. - Drug Profiles 17
AG-1321001 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
AG-1321001SY 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
AGDNCE-905 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
AGENCE-103 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
AGNBP-006 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
AGNBS-002 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
AGNBT-003 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
AGNCA-805 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
AGNDA-802 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
AGNDF-905 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
AGNDL-904 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
AGNDP-803 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
AGNES-101 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
AGNMS-004 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
AGNPN-803 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
AGNSG-005 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
AGPPC-709 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
AGSAA-010 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
AGSAV-301 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
carvedilol 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
doxazosin 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
felodipine 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
pantoprazole 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
theobromine 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline Analysis 41
Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline Products by Therapeutic Class 41
Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline Products By Target 44
Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 45
Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline Products By Mechanism of Action 46
Ahn-Gook Pharmaceutical Co., Ltd. - Locations And Subsidiaries 48
Head Office 48
Other Locations and Subsidiaries 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51



List of Tables

Ahn-Gook Pharmaceutical Co., Ltd., Key Information 6
Ahn-Gook Pharmaceutical Co., Ltd., Key Facts 6
Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline by Indication, 2013 9
Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2013 10
Ahn-Gook Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2013 11
Ahn-Gook Pharmaceutical Co., Ltd. - Phase III, 2013 12
Ahn-Gook Pharmaceutical Co., Ltd. - Phase II, 2013 13
Ahn-Gook Pharmaceutical Co., Ltd. - Phase I, 2013 14
Ahn-Gook Pharmaceutical Co., Ltd. - Preclinical, 2013 15
Ahn-Gook Pharmaceutical Co., Ltd. - Discovery, 2013 16
Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline By Therapeutic Class, 2013 42
Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline By Target, 2013 44
Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline By Route of Administration, 2013 45
Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline Products By Mechanism of Action, 2013 47
Ahn-Gook Pharmaceutical Co., Ltd., Other Locations 48



List of Figures

Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline by Indication, 2013 8
Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2013 10
Ahn-Gook Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2013 11
Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline By Therapeutic Class, 2013 41
Ahn-Gook Pharmaceutical Co., Ltd. - Pipeline Products By Mechanism of Action, 2013 46



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.